×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: Gene Silencing Therapy for Neurodegenerative Diseases
therapeutic
957 words
KG: Gene Silencing Therapy for Neurodegenerative Diseases
2026-03-22
kind:therapeutic
section:therapeutics
state:published
Contents
Gene Silencing Therapy for Neurodegenerative Diseases
💊
Therapeutic Info
Name
Gene Silencing Therapy for Neurodegenerative Diseases
Summary
Page for Gene Silencing Therapy for Neurodegenerative Diseases
Knowledge Graph
Related Hypotheses (30)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49
Chaperone-Mediated APOE4 Refolding Enhancement
Score: 0.48
APOE Isoform Conversion Therapy
Score: 0.44
Smartphone-Detected Motor Variability Correction
Score: 0.56
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.45
Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.44
Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53
Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo
Score: 0.47
Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.68
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65
CYP46A1 Overexpression Gene Therapy
Score: 0.63
Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflam
Score: 0.62
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
PARP1 Inhibition Therapy
Score: 0.58
TREM2-Mediated Cholesterol Dysregulation in Microglial Senes
Score: 0.57
CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microgli
Score: 0.57
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.55
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.51
Heat Shock Protein 70 Disaggregase Amplification
Score: 0.51
Proteostasis Enhancement via APOE Chaperone Targeting
Score: 0.50
Ganglioside Rebalancing Therapy
Score: 0.50
Lysosomal Calcium Channel Modulation Therapy
Score: 0.49
Orexin-Microglia Modulation Therapy
Score: 0.49
Microglial Purinergic Reprogramming
Score: 0.48
Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.48
Show 25 more
Related Analyses (29)
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
Senescent cell clearance as neurodegeneration therapy
neurodegeneration · archived
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Show 24 more
Related Experiments (7)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Longitudinal TLR2 reporter gene study in α-synuclein mice
validation · proposed · Score: 0.90
Dexamethasone treatment study in α-synuclein mice
validation · proposed · Score: 0.85
TLR expression in α-synuclein overexpressing mice
validation · proposed · Score: 0.80
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne
validation · proposed · Score: 0.40
Metal Ion Homeostasis Dysregulation in Alzheimer's Disease
validation · proposed · Score: 0.40
Show 2 more
See Also (15)
BEACoN Study - Biomarker Exploration in Aging, Cognitio
clinical · Pages share 5 hypotheses
LX1001 Long-Term Follow-up (NCT05400330) - Gene Therapy
clinical · Pages share 4 hypotheses
LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for
clinical · Pages share 4 hypotheses
Wnt/β-Catenin Signaling Pathway in Neurodegeneration
mechanism · Pages share 3 hypotheses
WNK1-Bilirubin Signaling in Neuroinflammation and Neuro
mechanism · Pages share 3 hypotheses
vip-vasoactive-intestinal-peptide-signaling-neurodegene
mechanism · Pages share 3 hypotheses
VEGF Signaling and Cerebral Angiogenesis in Neurodegene
mechanism · Pages share 3 hypotheses
Vagus Nerve Pathway in Neurodegeneration
mechanism · Pages share 3 hypotheses
Ubiquitin-Proteasome System Dysfunction in Neurodegener
mechanism · Pages share 3 hypotheses
ubiquitin-proteasome-dysfunction-neurodegeneration
mechanism · Pages share 3 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
mechanism · Pages share 3 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
mechanism · Pages share 3 hypotheses
Therapeutic Targets in Neurodegeneration
mechanism · Pages share 3 hypotheses
Tertiary Lymphoid Organs in Neurodegeneration
mechanism · Pages share 3 hypotheses
T-Cell Dysfunction in Neurodegeneration
mechanism · Pages share 3 hypotheses
Show 10 more